Encinas, CristinaHernandez Rivas, José ÁngelOriol, AlbertRosiñol Dachs, LauraBlanchard, María JesúsBellón, José MaríaGarcía Sanz, RamónRubia, Javier de laLópez de la Guía, AnaJímenez Ubieto, AnaJarque, IsidroIñigo, BelénDourdil, VictoriaArriba, Felipe deCuéllar Pérez-Ávila, ClaraGonzalez, YolandaHernández, Miguel TeodoroBargay, JoanGranell, MiguelRodríguez Otero, PaulaSilvent, MaialenCabrera, CarmenRios, RafaelAlegre, AdriánGironella, MercedesGonzalez, Marta SoniaSureda, AnnaSampol, AntoniaOcio, Enrique M.Krsnik, IsabelGarcía, AntonioGarcía Mateo, AránzazuSoler, Joan AlfonsMartín, JesúsArguiñano Pérez, José MªMateos, María VictoriaBladé, J. (Joan)San Miguel, Jesús F.Lahuerta, Juan JoséMartínez López, JoaquínGem/pethema (Grupo Español de Mieloma/Programa para el estudio de la terapéutica en hemopatías malignas) Cooperative Study Group2022-05-132022-05-132022-04-012044-5385https://hdl.handle.net/2445/185581Infections remain a common complication in patients with multiple myeloma (MM) and are associated with morbidity and mortality. A risk score to predict the probability of early severe infection could help to identify the patients that would benefit from preventive measures. We undertook a post hoc analysis of infections in four clinical trials from the Spanish Myeloma Group, involving a total of 1347 patients (847 transplant candidates). Regarding the GEM2010 > 65 trial, antibiotic prophylaxis was mandatory, so we excluded it from the final analysis. The incidence of severe infection episodes within the first 6 months was 13.8%, and majority of the patients experiencing the first episode before 4 months (11.1%). 1.2% of patients died because of infections within the first 6 months (1% before 4 months). Variables associated with increased risk of severe infection in the first 4 months included serum albumin <= 30 g/L, ECOG > 1, male sex, and non-IgA type MM. A simple risk score with these variables facilitated the identification of three risk groups with different probabilities of severe infection within the first 4 months: low-risk (score 0-2) 8.2%; intermediate-risk (score 3) 19.2%; and high-risk (score 4) 28.3%. Patients with intermediate/high risk could be candidates for prophylactic antibiotic therapies.8 p.application/pdfengcc by (c) Encinas, Cristina et al, 2022http://creativecommons.org/licenses/by/3.0/es/Mieloma múltipleAntibiòticsMultiple myelomaAntibioticsinfo:eu-repo/semantics/article2022-05-12info:eu-repo/semantics/openAccess35440057